Physician profile
Michael Sullivan
NPI 1144282096
$4,131.44
in general payments reported to CMS, 2019-2025
24 companies · $842 in 2025
The $842 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $275 · 2021: $193 · 2022: $240 · 2023: $197 · 2024: $1,996 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,143 · Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,142.92 |
| Food and Beverage | $892.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Consortium of Independent Immunology Clinics, LLC | $2,142.92 | 2024-2025 | |
| Genzyme Corporation | $665.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $391.94 | 2019-2025 | Fasenra |
| Novartis Pharmaceuticals Corporation | $124.69 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $96.81 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $87.80 | 2019-2025 | Nucala |
| Abbvie INC. | $68.77 | 2022-2023 | Rinvoq |
| Hospira, INC. | $65.92 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.52 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $55.26 | 2019-2022 | |
| Pfizer INC. | $49.42 | 2021-2023 | |
| Amgen INC. | $48.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.95 | 2020-2021 | |
| Pharming Healthcare, INC. | $30.90 | 2020-2023 | Ruconest |
| Csl Behring | $29.41 | 2023 | Hizentra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $28.25 | 2019-2023 | Xembify |
| Genentech USA, INC. | $26.13 | 2021-2022 | |
| Optinose US, INC. | $23.78 | 2024 | |
| Tersera Therapeutics LLC | $23.10 | 2025 | Zoladex |
| Philips North America LLC | $21.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.11 | 2020 | |
| Horizon Therapeutics Plc | $12.97 | 2021 | |
| Biocryst US Sales Co., LLC | $12.10 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,878.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.